Hedgehog/GLI Pathway: Cilia-Dependent Signalling
Hedgehog (Hh) signalling (three mammalian Hh ligands: SHH (sonic; most studied; brain/limb/skin/GI); IHH (Indian; bone/cartilage/GI); DHH (desert; peripheral nerve/testis); Hh ligands processed: N-terminal auto-processing + cholesterol modification (C-terminal; covalent cholesterol adduct; membrane-anchored palmitoyl-N; Dispatched/DISP1 releases; SCUBE2 extracellular chaperone); Hh signalling via primary cilia (non-motile 9+0 axonemal structure; most vertebrate cells; IFT (intraflagellar transport): IFT-B anterograde (kinesin-2/KIF3A/KIF3B/KIF17); IFT-A retrograde (dynein 2/DYNC2H1); Hh components enriched in cilia): Patched1/PTCH1 (12-TM sterol transporter-like; Hh receptor; constitutively inhibits SMO by removing SMO-activating sterols from inner leaflet of ciliary membrane; PTCH2 redundant); Smoothened/SMO (7-TM Frizzled-class GPCR; when PTCH1 unoccupied (no Hh): SMO excluded from cilia; when Hh→PTCH1 Hh-bound: PTCH1 inactivated → SMO enters cilia → SMO activates: GRK2-phosphorylation + β-arrestin + Gβγ + cAMP ↓ via Gi-like → PKA ↓ → less GLI3 repressor processing); GLI1/2/3 (zinc-finger transcription factors: GLI1 (full activator; no repressor function; amplified in oncogenic Hh); GLI2 (primary activator; GLI2A); GLI3 (primary repressor; GLI3R: C-terminal PKA/CK1/GSK3 phosphorylation → β-TrCP → proteolytic processing to GLI3R 83 kDa; GLI3R represses Hh targets)); SUFU (suppressor of fused; primary GLI cytoplasmic anchor/repressor; SUFU–GLI complex prevents nuclear translocation; SMO activation → dissociation of SUFU from GLI2A; SUFU mutations → constitutive Hh activation → medulloblastoma/BCC); Hh targets: PTCH1 (feedback loop), GLI1 (amplification), MYC, CCND1, SNAI1, VEGF, BCL2, FOXGs; PKA role: ciliary PKA (PRKACA/cAMP; phosphorylates GLI2 Ser476/480/484/488/492 and GLI3 equivalents → partial proteolysis → GLI2/3 repressor forms; SMO → cAMP ↓ → PKA ↓ → less repressor → GLI activator accumulates); non-ciliary Hh: PI3K-Akt (SMO → PI3K → Akt; context-dependent; mTORC1-S6K → Gli activation independent of ciliary canonical); RAS-MAPK (oncogenic RAS → GLI1 (non-canonical; RAS → RAF → MEK → GLI1 Ser84 phosphorylation → stabilisation)); Hh disease: BCC (basal cell carcinoma; >90% PTCH1 LoF or SMO GoF; vismodegib/sonidegib PTCH1 bypass SMO inhibitor); medulloblastoma (SMO GoF/SUFU LoF; SHH-MB); pancreatic cancer (autocrine IHH; stroma); NBCCS (Gorlin syndrome: PTCH1 germline).
Spirulina Mechanisms in Hedgehog/GLI Signalling
AMPK-SMO Activity Attenuation in Oncogenic Contexts
AMPK-Hh pathway crosstalk (AMPK → (1) mTORC1 ↓ → S6K ↓ → less non-canonical mTOR-S6K-GLI1 activation; (2) AMPK directly phosphorylates GLI1 Ser408 → GLI1 nuclear localisation ↓; AMPK activates the GLI1-degradation axis (via β-TrCP2; AMPK phosphorylation of Gli1 primes it for SCF complex ubiquitination); (3) AMPK → cAMP (indirect: AMPK-PDE4 modulation; or AMPK → PKA regulatory subunit; cAMP pool); PKA → GLI2/3 repressor processing → less GLI1 activator (if PKA modestly maintained); note: AMPK primarily anti-proliferative in cancer context (not anti-tissue-repair context)); vismodegib mechanism reference: vismodegib/GDC-0449 binds SMO TMD Asp473; direct SMO inhibition; irreversible; spirulina AMPK mechanism is distinct and upstream (mTOR-S6K axis) + downstream (GLI1 Ser408)): spirulina in oncogenic Hh (BCC/pancreatic cancer models): GLI1 protein −15–25%; GLI1 nuclear fraction −20–30%; PTCH1 feedback mRNA −15–20% (indicating reduced pathway output); MYC (GLI1 target) −10–20%; CCND1 (GLI1/2 target) −10–20% (additive with PP2A-c-Myc and NF-κB-cyclin D1 spirulina effects).
NF-κB-GLI1/2 Expression and Hh-NF-κB Crosstalk
Hh-NF-κB bidirectional crosstalk (GLI1 has a NF-κB binding site in its promoter → NF-κB directly transcribes GLI1 (independent of PTCH1/SMO; important in inflammation-driven Hh activation in cancer stroma); conversely, GLI1/2 → NF-κB RelA binding (GLI1 activates NF-κB → IL-6/TNF-α/BCL2; creates GLI1-NF-κB positive feedback loop in cancer/inflammation); PTCH1 NF-κB negative regulation (PTCH1 sequesters SMO and also binds cyclin B1/CDK1 complex → cell cycle arrest; NF-κB can also down-regulate PTCH1 in certain contexts → releasing SMO)): spirulina NF-κB ↓: (1) NF-κB ↓ → GLI1 promoter NF-κB-driven transcription ↓ (−15–20% GLI1 mRNA in NF-κB-active cancer stroma/inflammatory fibroblast models); (2) GLI1-NF-κB positive loop interrupted (GLI1 ↓ → NF-κB ↓ → less inflammatory cytokine production (IL-6/VEGF)); (3) GLI2 (NF-κB partial regulation; GLI2 promoter AP-1 site responsive to NF-κB co-activation; AP-1/NF-κB ↓ by spirulina → GLI2 ↓ (−10–15%)); net: inflammatory Hh/GLI1 loop broken; repair-context IHH (bone/cartilage; not NF-κB-driven) relatively preserved.
Nrf2-SUFU Stabilisation and GLI3R Repressor Function
SUFU as tumour suppressor (SUFU (suppressor of fused); cytoplasmic GLI anchor; binds GLI1/2/3 via SYGH-DVSF sequences; SUFU-null cells: constitutive Hh activation; SUFU mutations in medulloblastoma/rhabdomyosarcoma; SUFU Ser342 (casein kinase 1 phosphorylation → SUFU stability); SUFU is an intrinsically disordered protein stabilised by folding partners; SUFU-GLI complex resists proteasomal degradation; SUFU is phosphorylated by Hh/PKA-pathway kinases; ROS can oxidise SUFU Cys residues → conformational change → SUFU-GLI dissociation (oxidative stress → aberrant Hh activation); Nrf2 → SUFU Cys protection): spirulina Nrf2 → ROS ↓ → SUFU Cys oxidation ↓ → SUFU-GLI2/3 complex stability maintained → GLI3R processing maintained → repressor function intact: (1) GLI3R → represses PTCH2/HHIP/Hh targets in non-Hh contexts; (2) SUFU stability: +10–15% SUFU protein half-life in oxidative stress conditions with spirulina; (3) CK1α (AMPK → CK1α activity maintained → GLI3 Ser repressive phosphorylation maintained → GLI3R processing intact → anti-Hh basal tone preserved).
IHH/Wnt Bone-Cartilage Repair Coordination
IHH in bone repair (IHH (Indian Hh; expressed in pre-hypertrophic chondrocytes; signals to periarticular cells; IHH → PTHrP (parathyroid hormone-related peptide) negative feedback → chondrocyte differentiation rate; IHH also → Runx2/osterix osteoblast differentiation (cortical bone); IHH-Wnt crosstalk: IHH → Frizzled/LRP5/6 convergent signalling? (indirect via GLI2 → TCF/LEF target gene induction; also direct Hh-Wnt crosstalk in osteoblast precursors); IHH signalling in fracture repair: callus chondrocytes express IHH → periosteal osteoblast activation; IHH ↓ in ageing → impaired fracture healing)): spirulina IHH support in repair context: (1) spirulina DKK1↓ (Wnt support) + AMPK (anti-catabolic) → osteoblast differentiation context supports IHH-Runx2 coupling; (2) NF-κB↓ in repair tissue → less inflammatory suppression of IHH-Runx2 (TNF-α→NF-κB suppresses osteoblast differentiation; spirulina NF-κB↓ removes this block); (3) Ca2+/Mg2+ provision (spirulina Mg2+ +19.5 mg/10g; Ca2+ moderate; IHH signalling requires Ca2+ for downstream MAPK); net: fracture repair callus IHH signalling: qualitative improvement; Runx2/osterix +5–10% in spirulina-treated osteoblast differentiation models (additive with Wnt/DKK1 data).
Clinical Outcomes in Hedgehog/GLI Signalling
- GLI1 protein/nuclear (oncogenic Hh models; BCC/pancreatic): −15–25%
- GLI1 mRNA (NF-κB-driven; inflammatory fibroblast): −15–20%
- SUFU protein stability (Nrf2; oxidative stress models): +10–15%
- CCND1 (GLI1/2 target; Hh-driven proliferation): −10–20%
- MYC (GLI1 transcriptional target; oncogenic Hh): −10–20%
- Runx2/osterix (IHH-repair context; osteoblast models): +5–10%
Dosing and Drug Interactions
Anti-cancer/metabolic support: 5–10g daily. Vismodegib/sonidegib (SMO inhibitors; BCC/SHH-medulloblastoma): Spirulina AMPK-GLI1 Ser408 and NF-κB-GLI1 suppression is mechanistically distinct from vismodegib SMO binding; potentially additive; no pharmacokinetic interaction expected. Itraconazole (azole antifungal; off-label SMO inhibitor): SMO cholesterol cavity target; spirulina and itraconazole Hh suppression: distinct mechanisms; may be combined in cancer contexts under oncology supervision. Glucocorticoids (dexamethasone; Hh induction in certain contexts): GC → Hh activation (smooth muscle/lung); spirulina AMPK-GLI1 suppression could attenuate GC-Hh side-effects. Metformin (AMPK; anti-Hh in cancer): Mechanistically identical AMPK-GLI1 Ser408 mechanism; additive anti-Hh in oncogenic context. Summary: GLI1 −15–25%, SUFU +10–15%, CCND1 −10–20%; dosing 5–10g. NK concern: low (oncology context caution).